SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Mattsson Mattias) srt2:(2015-2019)"

Sökning: WFRF:(Mattsson Mattias) > (2015-2019)

  • Resultat 1-10 av 32
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  •  
4.
  •  
5.
  • Baliakas, Panagiotis, et al. (författare)
  • Prognostic indices in chronic lymphocytic leukaemia : where do we stand how do we proceed?
  • 2016
  • Ingår i: Journal of Internal Medicine. - : Wiley. - 0954-6820 .- 1365-2796. ; 279:4, s. 347-357
  • Forskningsöversikt (refereegranskat)abstract
    • The remarkable clinical heterogeneity in chronic lymphocytic leukaemia (CLL) has highlighted the need for prognostic and predictive algorithms that can be employed in clinical practice to assist patient management and therapy decisions. Over the last 20 years, this research field has been rewarding and many novel prognostic factors have been identified, especially at the molecular genetic level. Whilst detection of recurrent cytogenetic aberrations and determination of the immunoglobulin heavy variable gene somatic hypermutation status have an established role in outcome prediction, next-generation sequencing has recently revealed novel mutated genes with clinical relevance (e.g. NOTCH1, SF3B1 and BIRC3). Efforts have been made to combine variables into prognostic indices; however, none has been universally adopted. Although a unifying model for all groups of patients and in all situations is appealing, this may prove difficult to attain. Alternatively, focused efforts on patient subgroups in the same clinical context and at certain clinically relevant 'decision points', that is at diagnosis and at initiation of first-line or subsequent treatments, may provide a more accurate approach. In this review, we discuss the advantages and disadvantages as well as the clinical applicability of three recently proposed prognostic models, the MD Anderson nomogram, the integrated cytogenetic and mutational model and the CLL-international prognostic index. We also consider future directions taking into account novel aspects of the disease, such as the tumour microenvironment and the dynamics of (sub)clonal evolution. These aspects are particularly relevant in view of the increasing number of new targeted therapies that have recently emerged.
  •  
6.
  •  
7.
  • Baliakas, Panagiotis, 1977-, et al. (författare)
  • Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia
  • 2019
  • Ingår i: Haematologica. - : Ferrata Storti Foundation (Haematologica). - 1592-8721 .- 0390-6078. ; 104:2, s. 360-369
  • Tidskriftsartikel (refereegranskat)abstract
    • Chronic lymphocytic leukemia (CLL) patients with differential somatic hypermutation status of the immunoglobulin heavy variable genes, namely mutated or unmutated, display fundamental clinico-biological differences. Considering this, we assessed prognosis separately within mutated (M-CLL) and unmutated (U-CLL) CLL in 3015 patients, hypothesizing that the relative significance of relevant indicators may differ between these two categories. Within Binet A M-CLL patients, besides TP53 abnormalities, trisomy 12 and stereotyped subset #2 membership were equivalently associated with the shortest time-to-first-treatment and a treatment probability at five and ten years after diagnosis of 40% and 55%, respectively; the remaining cases exhibited 5-year and 10-year treatment probability of 12% and 25%, respectively. Within Binet A U-CLL patients, besides TP53 abnormalities, del(11q) and/or SF3B1 mutations were associated with the shortest time-to-first-treatment (5- and 10-year treatment probability: 78% and 98%, respectively); in the remaining cases, males had a significantly worse prognosis than females. In conclusion, the relative weight of indicators that can accurately risk stratify early-stage CLL patients differs depending on the somatic hypermutation status of the immunoglobulin heavy variable genes of each patient. This finding highlights the fact that compartmentalized approaches based on immunogenetic features are necessary to refine and tailor prognostication in CLL.
  •  
8.
  •  
9.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 32
Typ av publikation
tidskriftsartikel (24)
konferensbidrag (3)
forskningsöversikt (3)
rapport (1)
bokkapitel (1)
Typ av innehåll
refereegranskat (18)
övrigt vetenskapligt/konstnärligt (13)
populärvet., debatt m.m. (1)
Författare/redaktör
Mattsson, Mattias (24)
Rosenquist, Richard (9)
Stamatopoulos, Kosta ... (7)
Mansouri, Larry (6)
Baliakas, Panagiotis (6)
Scarfo, Lydia (5)
visa fler...
Ghia, Paolo (5)
Smedby, Karin E. (4)
Juliusson, Gunnar (4)
Hansson, Lotta (4)
Xochelli, Aliki (4)
Asklid, Anna (4)
Osterborg, Anders (3)
Ghia, P (3)
Scarfo, L (3)
Sutton, Lesley-Ann (3)
Hadzidimitriou, Anas ... (3)
Anagnostopoulos, Ach ... (3)
Pospisilova, Sarka (3)
Baliakas, Panagiotis ... (3)
Stavroyianni, Niki (3)
Oscier, David (3)
Blennow, Kaj, 1958 (2)
Zetterberg, Henrik, ... (2)
Rääf, Christopher (2)
Mattsson, Sören (2)
Hägglund, Hans (2)
Hadzidimitriou, A (2)
Davis, Z (2)
Anagnostopoulos, A (2)
Juliusson, G (2)
Pospisilova, S (2)
Belessi, C (2)
Agathangelidis, A (2)
Agathangelidis, Andr ... (2)
Davi, Frederic (2)
Minga, E. (2)
Plevova, K. (2)
Trentin, L. (2)
Oscier, D. (2)
Belessi, Chrysoula (2)
Davis, Zadie (2)
Hansson, Oskar (2)
Smedby, KE (2)
Wennerås, Christine, ... (2)
Andersson, Per Ola (2)
Andersson, P O (2)
Sutton, LA (2)
Plevova, Karla (2)
Minga, Eva (2)
visa färre...
Lärosäte
Uppsala universitet (24)
Karolinska Institutet (14)
Lunds universitet (7)
Linköpings universitet (5)
Göteborgs universitet (4)
Umeå universitet (2)
visa fler...
Sveriges Lantbruksuniversitet (2)
Luleå tekniska universitet (1)
Örebro universitet (1)
Chalmers tekniska högskola (1)
Karlstads universitet (1)
visa färre...
Språk
Engelska (31)
Svenska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (28)
Naturvetenskap (4)
Samhällsvetenskap (2)
Teknik (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy